Melissa Ledgerwood-Lee

Dr. Melissa Ledgerwood-Lee

Medicine, University of California, San Diego, San Diego, California, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
AZAli Zifan
Ali Zifan
MLMelissa Ledgerwood-Lee
Melissa Ledgerwood-Lee
RMRavinder K. Mittal
Ravinder K. Mittal

24 January 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
MLMelissa Ledgerwood-Lee
Melissa Ledgerwood-Lee
AZAli Zifan
Ali Zifan
DKDavid C. Kunkel
David C. Kunkel
RSRobert Sah
Robert Sah
RMRavinder K. Mittal
Ravinder K. Mittal

1 October 2023 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
RMRavinder K. Mittal
Ravinder K. Mittal
MLMelissa Ledgerwood-Lee
Melissa Ledgerwood-Lee
MCMichelle Caplin
Michelle Caplin
PXPudan Xu
Pudan Xu
WMWalter Marquez-Lavenant
Walter Marquez-Lavenant
AZAli Zifan
Ali Zifan
Swallow-related axial shortening of the esophagus is reduced, and there is no separation between the lower esophageal sphincter and crural diaphragm (CD) with swallowing in patients with achalasia esophagus. Fat in the hiatal opening of the esophagus appears to be replaced with fibrous tissue in patients with achalasia, resulting in tight anchoring between the LES and CD. The above findings explain low prevalence of hiatus hernia and the low compliance of the LES in achalasia esophagus.

29 December 2020 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
MLMelissa Ledgerwood-Lee
Melissa Ledgerwood-Lee
AZAli Zifan
Ali Zifan
WLWilliam Lin
William Lin
JAJesse de Alva
Jesse de Alva
HCHaojin Chen
Haojin Chen
RMRavinder K. Mittal
Ravinder K. Mittal

18 December 2022 in Viruses
Verified
Journal Article
Open access
PDF file
BJBruna Andersen Pereira de Jesus
Bruna Andersen Pereira de Jesus
AGAnderson Albino Gomes
Anderson Albino Gomes
ACAlex E. Clark
Alex E. Clark
TRTayse Andrade Rodrigues
Tayse Andrade Rodrigues
MLMelissa Ledgerwood-Lee
Melissa Ledgerwood-Lee
Partha RayPartha Ray
Partha Ray
The recent development and mass administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines allowed for disease control, reducing hospitalizations and mortality. Most of these vaccines target the SARS-CoV-2 Spike (S) protein antigens, culminating with the production of neutralizing antibodies (NAbs) that disrupt the attachment of the virus to ACE2 receptors on the host cells. However, several studies demonstrated that the NAbs typically rise within a few weeks after vaccination but quickly reduce months later. Thus, multiple booster administration is recommended, leading to vaccination hesitancy in many populations. Detecting serum anti-SARS-CoV-2 NAbs can instruct patients and healthcare providers on correct booster strategies. Several in vitro diagnostics kits are available; however, their high cost impairs the mass NAbs diagnostic testing. Recently, we engineered an ACE2 mimetic that interacts with the Receptor Binding Domain (RBD) of the SARS-2 S protein. Here we present the use of this engineered mini-protein (p-deface2 mut) to develop a detection assay to measure NAbs in patient sera using a competitive ELISA assay. Serum samples from twenty-one patients were tested. Nine samples (42.8%) tested positive, and twelve (57.1%) tested negative for neutralizing sera. The data correlated with the result from the standard commercial assay that uses human ACE2 protein. This confirmed that p-deface2 mut could replace human ACE2 in ELISA assays. Using bacterially expressed p-deface2 mut protein is cost-effective and may allow mass SARS-CoV-2 NAbs detection, especially in low-income countries where economical diagnostic testing is crucial. Such information will help providers decide when a booster is required, reducing risks of reinfection and preventing the administration before it is medically necessary.

24 April 2024 in Viruses
Verified
Journal Article
Open access
PDF file
Partha RayPartha Ray
Partha Ray
MLMelissa Ledgerwood-Lee
Melissa Ledgerwood-Lee
HBHoward Brickner
Howard Brickner
ACAlex E. Clark
Alex E. Clark
AGAaron Garretson
Aaron Garretson
ESEliah aronoff Spencer
Eliah aronoff Spencer
The continuing mutability of the SARS-CoV-2 virus can result in failures of diagnostic assays. To address this, we describe a generalizable bioinformatics-to-biology pipeline developed for the calibration and quality assurance of inactivated SARS-CoV-2 variant panels provided to Radical Acceleration of Diagnostics programs (RADx)-radical program awardees. A heuristic genetic analysis based on variant-defining mutations demonstrated the lowest genetic variance in the Nucleocapsid protein (Np)-C-terminal domain (CTD) across all SARS-CoV-2 variants. We then employed the Shannon entropy method on (Np) sequences collected from the major variants, verifying the CTD with lower entropy (less prone to mutations) than other Np regions. Polyclonal and monoclonal antibodies were raised against this target CTD antigen and used to develop an Enzyme-linked immunoassay (ELISA) test for SARS-CoV-2. Blinded Viral Quality Assurance (VQA) panels comprised of UV-inactivated SARS-CoV-2 variants (XBB.1.5, BF.7, BA.1, B.1.617.2, and WA1) and distractor respiratory viruses (CoV 229E, CoV OC43, RSV A2, RSV B, IAV H1N1, and IBV) were assembled by the RADx-rad Diagnostics core and tested using the ELISA described here. The assay tested positive for all variants with high sensitivity (limit of detection: 1.72–8.78 ng/mL) and negative for the distractor virus panel. Epitope mapping for the monoclonal antibodies identified a 20 amino acid antigenic peptide on the Np-CTD that an in-silico program also predicted for the highest antigenicity. This work provides a template for a bioinformatics pipeline to select genetic regions with a low propensity for mutation (low Shannon entropy) to develop robust ‘pan-variant’ antigen-based assays for viruses prone to high mutational rates.